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Abstract
Bovine viral diarrhea virus (BVDV) plays a key role in bovine respiratory disease complex,
which can lead to pneumonia, diarrhea and death of calves. Current vaccines are not very
effective due, in part, to immunosuppressive traits and failure to induce broad protection.
There are diverse BVDV strains and thus, current vaccines contain representative genotype
1 and 2 viruses (BVDV-1 & 2) to broaden coverage. BVDV modified live virus (MLV) vac-
cines are superior to killed virus vaccines, but they are susceptible to neutralization and
complement-mediated destruction triggered by passively acquired antibodies, thus limiting
their efficacy. We generated three novel mosaic polypeptide chimeras, designated
NproE2123; NS231; and NS232, which incorporate protective determinants that are highly con-
served among BVDV-1a, 1b, and BVDV-2 genotypes. In addition, strain-specific protective
antigens from disparate BVDV strains were included to broaden coverage. We confirmed
that adenovirus constructs expressing these antigens were strongly recognized by monoclo-
nal antibodies, polyclonal sera, and IFN-γ-secreting T cells generated against diverse
BVDV strains. In a proof-of-concept efficacy study, the multi-antigen proto-type vaccine
induced higher, but not significantly different, IFN-γ spot forming cells and T-cell proliferation
compared to a commercial MLV vaccine. In regards to the humoral response, the prototype
vaccine induced higher BVDV-1 specific neutralizing antibody titers, whereas the MLV vac-
cine induced higher BVDV-2 specific neutralizing antibody titers. Following BVDV type 2a
(1373) challenge, calves immunized with the proto-type or the MLV vaccine had lower clini-
cal scores compared to naïve controls. These results support the hypothesis that a broadly
protective subunit vaccine can be generated using mosaic polypeptides that incorporate
rationally selected and validated protective determinants from diverse BVDV strains. Fur-
thermore, regarding biosafety of using a live vector in cattle, we showed that recombinant
human adenovirus-5 was cleared within one week following intradermal inoculation.
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Introduction
Bovine viral diarrhea virus (BVDV), an infectious pathogen that is prevalent in cattle herds
globally, is a key agent responsible for causing Bovine Respiratory Disease Complex (BRDC)
[1]. Infection with BVDV can cause severe diarrhea, respiratory disease, immunosuppression,
abortion, congenital malformations, and birth of persistently infected (PI) calves, which play a
major role in virus transmission in herds [2]. Immunosuppression caused by acute infection
of unprotected calves allows secondary infections to establish and cause pneumonia or enteri-
tis [3]. The secondary infections are responsible for high rates of morbidity and mortality, and
it is estimated that the U.S. livestock industry loses >$1billion annually due to BRDC [4, 5].
This virus is classified as a member of the genus Pestivirus within the family Flaviviridae
[6]. Two BVDV genotypes (type 1 and 2) are recognized according to serological and genetic
relatedness [7]. The BVDV isolates circulating in the world are heterogeneous: BVDV geno-
type 1 (BVDV-1) is subdivided into a minimum of 12 sub-genotypes (BVDV1a, b, c.. . .l),
whereas BVDV genotype 2 (BVDV-2) is classified into 4 subtypes, 2a-2d [8, 9]. The BVDV can
also be divided into cytopathic and non-cytopathic biotypes (cpBVDV and ncpBVDV, respec-
tively), based on their lytic effects on infected cells. The BVDV isolates cause a wide range of
disease manifestations, which include sub-clinical and persistent infections, fetal infections,
and host immunosuppression [10]. Infected cattle begin to shed the virus into the environ-
ment for about ten continuous days starting as early as four days after subclinical infection,
whereas PI animals shed the virus for their entire lifetime [11, 12]. The prevalence of PI ani-
mals in selected herds in the United States is estimated at 1.7% of the cattle population, and
these animals are considered to be the primary source of infection of susceptible animals [13].
BVDV infection in cattle induces high titers of neutralizing antibodies that prevent reinfec-
tions especially with the same genotype/sub-genotype [14, 15]. Some studies have demon-
strated prevention of clinical signs, but not viral shedding, in cattle upon challenge with
BVDV-2 following immunization with BVDV-1 [16, 17]. Failure of vaccination has been
attributed to infection with variant genotype(s) as well as development of antigenically distinct
viruses in exposed animals [18, 19]. Individual PI cattle may also be a source of genetic variants
that amplify following infection of susceptible cattle [20, 21]. However, in the absence of neu-
tralizing antibodies, mutations occur faster and more frequently in BVDV following infection
of pregnant animals [22]. Many of the virus genome mutations result in amino acid changes in
E2 glycoprotein, a key target of the neutralizing antibodies [21, 23]. The E2 glycoprotein is
highly immunogenic and at least nine epitopes have been mapped within three antigenic
domains [24–28]. One of these antigenic determinants is immunodominant in BVDV-1 and
there are three in BVDV-2 that induce neutralizing antibodies in animals [25]. However, it is
also reported that viremia can occur despite the presence of neutralizing antibodies in infected
animals, and some animals can be protected against BVDV infection in the absence of E2-spe-
cific neutralizing antibodies, suggesting a role for neutralizing epitopes from other antigens
and/or T cells in protection [29, 30]. Clearance of BVDV infections has also been associated
with strain-specific MHC-restricted CD4+ and CD8+ T-cell responses [15, 31]. Cell mediated
response to infection is initially provided by E2 and NS2-3 antigen-specific helper CD4+ T-
cells [32–34].
Despite availability of vaccines, BVDV prevalence has not markedly reduced due, in part, to
failure of the vaccines to confer broad protection [35, 36]. Currently, both killed and modified
live virus (MLV) vaccines are commercially available [37]. The killed vaccine elicits primarily a
humoral response with minimal cell mediated response, whereas MLV vaccines are better at
inducing CD4+ and CD8+ T-cells responses in addition to antibody responses [38]. Since the
presence of BVDV-specific maternal antibodies interferes with efficacy of BVDV vaccines,
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especially MLV, immunization is usually delayed until most of the maternal BVDV antibodies
have waned [19, 39]. However, BVDV-specific antibodies in each animal decline at different
rates and thus, antibody titers in some calves fall below protective levels much earlier than
expected, and in the presence of PI calves in the herd, there is a high risk of infection [40].
MLV vaccines are currently the most efficacious, but genotype-specific vaccines are not effec-
tive at conferring cross-protection and thus, protection against BVDV-1 and 2 requires a vac-
cine formulation that contains a representative of genotype type 1 and 2 viruses. The MLV
vaccines are not considered to be safe since the attenuated virus can revert to wild type virus,
cause in-utero infections and mucosal disease, carry the risk of vaccine contamination with
adventitious viruses, and are immunosuppressive [41, 42]. Furthermore, MLV strains may
cause ovarian lesions leading to infertility in cows [43]. Both killed and MLV vaccine virus are
traditionally grown in MDBK cells and recent findings show that calves fed colostrum from
some dams vaccinated with killed BVDV vaccine formulated with adjuvant have a high inci-
dence of a syndrome characterized by spontaneous bleeding, severe anemia with heavy bone
marrow damage. There is evidence to show that the damage is due to maternal alloantibodies
induced by the vaccines against bovine cell antigens, including MHC-I molecules, and the syn-
drome has been named bovine neonatal pancytopenia [44–46].
Given the limitations of the current vaccines, there is a need to develop improved vaccines
for safe, robust, and broad protection against diverse BVDV genotypes. Empirical selection
and validation of protective immune targets that are conserved among diverse BVDV strains
can be used to generate novel mosaic antigens for development of a contemporary vaccine.
Similar strategies have been used to develop broadly protective vaccines to overcome a wide
Influenza and HIV-1 genetic diversity [47–49]. The BVDV envelop (E2) and non-structural
(NS2-3) antigens are immunodominant, and neutralizing antibody as well as T-cell responses
directed against these antigens can confer protection [50, 51]. Importantly, evaluation of
BVDV-specific immune responses following resolution of acute infection has revealed that the
E2, NS2-3, and N-terminal protease fragment (Npro) antigens contain CD4+ T-cell epitopes
[31]. In addition, MHC DR-restricted T-cell epitopes have been identified from conserved
regions of E2 and NS2-3 [31, 34, 51–53].
In this study, we generated a prototype vaccine composed of recombinant adenoviruses
expressing three novel mosaic polypeptide chimeras, designated NproE2123; NS231; and NS232.
These antigens incorporated neutralizing epitopes, defined and predicted IFN-γ-inducing
CD4+ T-cell as well as cytotoxic T lymphocyte determinants that are highly conserved among
BVDV-1a, b, and BVDV-2 genotypes [24, 25, 31, 51, 52]. In addition, strain-specific protective
antigens from disparate BVDV strains whose genome sequences are available were included to
broaden coverage. We compared the immunogenicity and protective efficacy of this prototype
adenovirus-vectored vaccine to a commercial MLV vaccine in calves.
Adenovirus-vectored subunit vaccines are undergoing clinical trials in readiness for deploy-
ment [54, 55]; there is concern that persistence of the construct in host tissues may increase
chances of generating replication-competent progenies if recombination with closely related
viruses occurs. Thus, we set out to determine replication-incompetent recombinant human
adenovirus-5 persistence at the skin injection site, the draining lymph node, and the spleen of
calves following intradermal inoculation.
Materials and Methods
Design of genes encoding novel mosaic BVDV antigens
Published reports on protective BVDV antibody and T-cell epitopes, sequenced genomes, and
bioinformatics tools were used to design novel mosaic polypeptides, which incorporated
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consensus and strain-specific key antigenic determinants from BVDV-1 and 2 strains [24, 25,
31, 47, 48, 52, 56, 57]. Analysis of sequenced genomes showed that the Npro antigen is highly
conserved, but the E2 and the NS2-3 antigens have conserved and variable domains. Amino
acid sequences of the E2 proteins from currently defined BVDV-1 or BVDV-2 genotypes were
aligned and three novel mosaic E2 polypeptides, designated E21,2,3 (E21-3), each containing
consensus E2 determinants plus defined strain-specific neutralization epitopes were selected,
and wherever there was no consensus at a specific amino acid position for the BVDV-1 geno-
types, amino acid from the BVDV-1b sequence was selected since this is the most prevalent
sub-type in North America. The E21-3 polypeptide sequence was fused in-frame to the C-ter-
mini of the Npro polypeptide and the resultant chimeric polypeptide, designated NproE21-3, was
used to generate a codon-optimized synthetic gene, designated npro-e21a-e21b-e22 (nproe21-3,),
that also included flag tag sequence at the 3’ end. Two additional mosaic polypeptides that
incorporated consensus amino acids from diverse NS2-3 proteins, designated NS2-31 (from
BVDV-1 genotypes) and NS2-32 (from BVDV-2 genotypes) were similarly designed and used
to generate two synthetic gene sequences, designated ns2-31, and ns2-32, respectively, that also
included the flag tag sequence at the 3’ end. Synthetic genes were codon-optimized, custom-
made, cloned into pUC57 vector, and sequence-verified by GenScript Inc., NJ, USA.
Generation of recombinant adenovirus plasmid expression constructs
The three synthetic genes (nproe21-3, ns2-31, and ns2-32) were subcloned into pDonR vector
using the Gateway Technology (Life Technologies, NY, USA) to generate shuttle constructs.
Positive clones were identified by PCR screening of plasmid DNA in bacteria colonies using
vector-specific forward primer and gene-specific reverse primer. Authentic entry constructs,
designated pDonRNproE21-3, pDonRNS2-31, and pDonRNS2-32, respectively were selected by
DNA sequencing. The selected constructs were used to transfer each gene into pAd adenovirus
plasmid backbone by homologous recombination (Gateway Technology, Life Technologies,
NY, USA) and recombinant constructs were identified by PCR screening as above. Authentic
recombinant plasmid constructs, designated pAdNproE21-3, pAdNS2-31, and pAdNS2-32,
respectively were selected after DNA sequencing.
Protein expression by plasmid constructs and generation of recombinant
adenoviruses
Protein expression was evaluated by immunocytometric analysis of human embryonic kidney
(HEK)-293A cells grown in 12-well tissue culture plates and transfected with 1 μg of the
selected clones of the pAd DNA constructs, and then probed with anti-FLAG mAb at 48 hr.
post-transfection as previously described [58]. Five clones of each pAd construct were selected
based on efficiency of protein expression as judged by the immunocytometric analysis, and
2 μg DNA of each construct was digested with Pac-I restriction enzyme. The digested DNA
was transfected into HEK-293A cells grown in 6-well plates to generate recombinant adenovi-
ruses that were designated AdNproE21-3, AdNS2-31, and AdNS2-32, respectively. In addition,
adenovirus expressing luciferase (AdLuc) was generated to serve as a negative control. Protein
expression by the AdNproE21-3, AdNS2-31, and AdNS2-32 adenoviruses was tested and validated
by immunocytometric analysis of infected HEK-293A cells as above, whereas fluorescence was
used to confirm luciferase expression.
One clone of each recombinant adenovirus was selected for amplification based on protein
expression. The bulk viruses were tested for protein expression as above and following titer
determination, replication competence of the recombinant adenoviruses was determined by
immunocytometric analysis of HEK-293A (which supports adenovirus replication) and
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MDBK cells (susceptible to adenovirus infection, but do not support replication of replication-
incompetent adenovirus) infected overnight with one MOI of each virus construct and then
probed with an in-house generated rabbit anti-adenovirus polyclonal IgG (1:500 dilution) fol-
lowed by an alkaline-phosphatase-conjugated anti-Rabbit IgG (1:1000) (Jackson ImmunoRe-
search, Cat #711-055-152) secondary antibody and Fast Red TR–Naphthol AS-MX as the
substrate (Sigma, F4523) to evaluate infectivity.
Validation of the mosaic antigens using BVDV-specific antibodies and T-
cells
Authenticity of the mosaic NproE21-3, NS2-31, and NS2-32 antigens was confirmed by immuno-
cytometric analysis using E2-specific neutralizing monoclonal antibodies (mAbs) and poly-
clonal antibodies (pAbs) generated against diverse BVDV strains. Briefly, HEK-293A cells
grown in 12-well plates were infected for 48 hr. with AdNproE21-3, AdNS2-31, AdNS2-32, or
AdLuc and probed with anti-BVDV E2 mAbs 348 and 26A (VMRD, Inc., Pullman, WA), goat
anti-BVDV polyclonal sera (VMRD), and bovine anti-BVDV hyperimmune sera from steers
immunized and challenged with multiple BVDV-1 and 2 strains [59]. Antigen authenticity was
further confirmed by ELISA and Western Blot analysis using the above mentioned antibodies.
The authenticity of the T-cell epitopes in the mosaic antigens was validated by proliferation
assays using peripheral blood mononuclear cells (PBMCs) isolated from the BVDV-immu-
nized steers [59]. Recombinant NproE21-3, NS2-31 and NS2-32 antigens were expressed by using
recombinant baculoviruses in High Five cells (Thermo Fisher Scientific) generated using the
Bac-to-Bac HBM TOPO Secreted Expression System (Thermo Fisher Scientific) as per manu-
facturer’s instructions and validated as above. These antigens were then affinity purified using
Anti-FLAG M2 Affinity Gel (Sigma) and used at 5μg/ml to conduct 3H-Thymidine incorpo-
ration assays to quantify antigen-specific T cell responses as previously described [58]. Heat
killed BVDV-1b (CA0401186a) and BVDV-2 (A125) at 5μg/ml served as positive control anti-
gens, whereas medium alone was the negative control. The outcome of the cell proliferation
was presented as counts per minute (cpm).
Immunization and challenge of calves
Three groups (A, B, and C), of age-matched BVDV sero-negative and virus-free weaned Hol-
stein calves (n = 5) were identified as previously described [60] and used in this study as shown
in Table 1. Each calf in group A was inoculated subcutaneously (SQ) with a cocktail, designated
AdBVDV, containing the AdNproE21-3, AdNS2-31, and AdNS2-32 recombinant adenoviruses (5
x 1010 TCID50/construct) formulated in adjuvant E (BenchMark-Vaxliant). Each calf in group
B was similarly inoculated, but with a commercial MLV BVDV-1 and 2 vaccine (Bovi-Shield
Gold™, Zoetis Inc., Kalamazoo, MI), whereas each calf in group C was inoculated with the
recombinant AdLuc formulated in adjuvant E. Seventy-nine days post-priming, the AdBVDV
vaccinees and the negative controls received inoculation of the respective priming immunogen
and dose as above. One hundred and forty nine days post-boosting, all the calves were chal-
lenged by intranasal administration of 2 x 106 TCID50 of BVDV-1373 using a human nasal
atomizer. (http://www.teleflexarcatalog.com/anesthesia-respiratory/airway/categories/552).
Cellular and humoral immune responses
Two weeks post-priming and bi-weekly thereafter, PBMCs were isolated to evaluate and quan-
tify proliferation of BVDV-specific T-cell responses as previously described [58]. The PBMCs
(2.5 x 105 cells/well) were cultured for 72 hr. at 37˚C in triplicate wells of round-bottom
96-well plates in a total volume of 100 μl of complete RPMI-1640 (cRPMI) medium containing
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2.5 μg/ml defined BVDV CD4+ T-cell epitope peptides [32]. The positive control was cRPMI
medium containing 1.3 μg/ml concanavalin A (ConA), whereas medium alone served as a neg-
ative control. Cells were labeled with 0.25 μCi of 3H-thymidine for 6 hr., harvested using a
semi-automatic cell harvester (Tomtec Life Sciences, Hamden, CT), and the incorporated 3H-
thymidine was counted with a Micro-Beta liquid scintillation counter (Perkin Elmer, Wal-
tham, MA). The incorporation of 3H-thymidine by the proliferating PBMCs was presented as
mean counts per minute (cpm) of triplicate wells (±1 SD).
The PBMCs were also used to quantify BVDV-specific IFN-γ-secreting cells by EliSpot
assay as previously described [58]. The PBMCs (2.5 x 105 cells/well) were seeded into triplicate
wells of MultiScreen-HA plates (EMD Millipore, Billerica, MA) in a final volume of 100 μl
cRPMI medium containing 2.5 μg/ml BVDV CD4+ T-cell epitope peptides. The positive con-
trol was 1.3 μg/ml ConA, whereas medium alone served as a negative control. The plates were
incubated for 36 hr. at 37˚C, washed, developed, and dried overnight as previously described
[58]. Following quantification of the spots using an EliSpot reader (AID, Diagnostika GmbH,
Germany), the mean number of spots in the negative control wells was subtracted from the
mean number of spots in the cognate test wells to determine the mean number of BVDV-spe-
cific IFN-γ-secreting PBMCs and the results were presented as the mean number of spot-form-
ing cells/106 PBMCs.
Sera from blood collected two weeks post-boost and one week pre-challenge were tested to
determine BVDV-1 and BVDV-2 neutralizing antibody titers using BVDV-1 (Singer, NADL,
BJ, TGAC, CA0401186a) and BVDV-2 (890, 1373, A125) strains as previously described [61,
62]. Briefly, serum was heat inactivated at 56˚C for 30 min, and 25 μl of each serum was serially
diluted (2-fold) in cell culture media without FBS in 96-well microtiter plates. Stock BVDV
virus containing 100 TCID50/25μl was added to each test well. In each test, a positive control
Table 1. Immunization Protocol.
Calf ID Vaccine-Prime Vaccine-Boost
4 AdBVDV AdBVDV
12 AdBVDV AdBVDV
13 AdBVDV AdBVDV
22 AdBVDV AdBVDV
23 AdBVDV AdBVDV
3 BVDV MLV -
14 BVDV MLV -
19 BVDV MLV -
24 BVDV MLV -
27 BVDV MLV -
10 AdLuciferase AdLuciferase
18 AdLuciferase AdLuciferase
25 AdLuciferase AdLuciferase
28 AdLuciferase AdLuciferase
29 AdLuciferase AdLuciferase
Calves in the treatment group were inoculated subcutaneously with a cocktail of the AdNproE21-3, AdNS2-31,
and AdNS2-32 recombinant adenoviruses (AdBVDV) expressing the BVDV antigens, whereas calves in the
positive control group received a commercial BVDV MLV vaccine. Calves in the negative control group were
inoculated with the recombinant AdLuc. The calves were boosted with the respective priming inoculum and
dose.
doi:10.1371/journal.pone.0170425.t001
Live-Vectored BVDV Multi-Antigen-Based Vaccine
PLOS ONE | DOI:10.1371/journal.pone.0170425 January 18, 2017 6 / 23
serum was also included. This serum/virus mixture was incubated for 1 hr., at 37˚C, MDBK
cells added, and the plates were incubated at 37˚C in a humidified atmosphere of 5% CO2 for
72 hr. The cells were observed daily for CPE for cytopathic strains, whereas the non-cytopathic
strains were detected by Immuno-peroxidase assay [63]. The results were presented as serum
neutralization titers (SNT) [64].
Clinical parameters: Viremia/WBC-platelet counts
Calves were observed daily pre-immunization, post-immunization and post-challenge for
coughing, nasal discharge and diarrhea. Rectal temperature post-challenge was taken daily
[65]. To determine virus titers post-challenge, blood was collected in vacutainer tubes (con-
taining Sodium-EDTA) by jugular venipuncture, freeze-thawed to lyse cells, centrifuged and
supernatants were used to determine BVDV titers as previously described [66]. Whole blood
was used to determine CBC using Cell-Dyn 3700 analyzer (Abbott Diagnostics, Lake Forest, IL
60045, USA) with veterinary package as bovines for automated counts (WBC, RBC, Hgb,
MCV, PLT). Thin blood smears were stained with Giemsa for differential white blood cell
counts [67]. Platelet count verification, WBC count verification, RBC and WBC morphology
was evaluated microscopically.
Persistence of recombinant adenovirus in cattle
Presence of recombinant replication-incompetent adenovirus in cattle was tracked for three
weeks post-inoculation by rescue of virus from tissue biopsies taken from the intradermal
inoculation site. Briefly, recombinant adenovirus (5 x 109 ifu) was inoculated (I.D) into nine
marked sites on the neck of four steers. One skin biopsy was taken from each site using a 4mm
Biopsy Punch (American Screening, Shreveport, LA) on days 1–7, 14, and 21. In addition, skin
biopsies were concurrently collected from the flank region of each steer to serve as negative
controls. The steers were euthanized three weeks post-inoculation and samples of draining
lymph node and spleen were collected. The fresh tissue samples collected were snap frozen in
liquid nitrogen, ground and then resuspended in 1 ml DMEM (Invitrogen). Following centri-
fugation, supernatants were filtered through 0.22 μm pore membrane, and 0.5 ml was added to
one well of HEK-293A cells (which supports adenovirus replication) grown in 12-well plates.
Supernatant from HEK-293A cells infected overnight with the recombinant adenovirus, and
subjected to the same treatment as above was used as a positive control. Three days post-infec-
tion, presence of adenovirus in the HEK-293A cells was evaluated by immunocytometric anal-
ysis using the rabbit anti-adenovirus polyclonal IgGs as above. Medium from the above HEK-
293A cells was used to infect fresh cells, and seven days later the above process was repeated to
confirm presence or absence of adenovirus.
Statistical analysis
Analysis of Variance (ANOVA) followed by Tukey’s multiple comparison test was used to ana-
lyze the significance of the differences in BVDV-specific immune responses and disease indi-
ces between the treatments (groups A and B) and the negative control (group C) using
GraphPad Prism 6 (Version 6.07, GraphPad Software, Inc. La Jolla, USA). Statistical signifi-
cance was considered when P < 0.05.
Ethics statement
The study was conducted in accordance with the Public Health Service Policy on Humane
Care and Use of Laboratory Animals as specified in the Health Research and Extension Act of
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1985 (Public Law 99–158) or in accordance with the U.S Department of Agriculture policies as
required by the Animal Welfare Act of 1966 (7.USC.2131 et seq) as amended in 1970, 1976,
and 1985. The research protocol: AUP21010-65 was reviewed and approved by the Texas
A&M University Institutional Animal Care and Use Committee to ensure compliance with
PHS standards. All animal care facilities are inspected twice per year. The facilities and proce-
dures for maintenance and care of animals are accredited by the American Association for
Accreditation of Laboratory Animal Care. Efforts were made to minimize suffering, and at the
completion of the study, the calves were euthanized with an overdose of sodium pentobarbital.
This method is approved by the Panel on Euthanasia of the American Veterinary Medical
Association.
Results and Discussion
Expression constructs encoding novel mosaic BVDV antigens
Three synthetic genes (designated nproe21-3, ns2-31, and ns2-32) encoding novel BVDV mosaic
antigens were designed as depicted in Fig 1A. The nproe21-3 chimeric gene encodes the N-ter-
minal protease fragment (Npro), a consensus BVDV-1a envelope glycoprotein E2 mosaic gene
(e21), a consensus BVDV-1b envelope glycoprotein E2 mosaic gene (e22), and a consensus
BVDV-2 envelope glycoprotein E2 mosaic gene (e23) fused in-frame to flag-tag. The ns2-31
DNA fragment encodes a consensus BVDV-1 Nonstructural protein 2–3 fused in-frame to
flag-tag, whereas the ns2-32 DNA fragment encodes a consensus BVDV-2 Nonstructural pro-
tein 2–3 fused in-frame to flag-tag (Fig 1A).
Expression of the mosaic BVDV antigens
Immunocytometric analysis of HEK-293A cells transfected with the pAdNproE21-3, pAdNS2-31,
or pAdNS2-32 constructs probed with anti-FLAG mAb confirmed that each construct
expressed the encoded antigen (Fig 1B). Similarly, immunocytometric analysis of HEK-293A
cells infected with the AdNproE21-3, AdNS2-31, or AdNS2-32 recombinant adenoviruses probed
with anti-FLAG mAb confirmed protein expression (Fig 1C). Analysis of replication compe-
tency confirmed that the AdNproE21-3, AdNS2-31, and AdNS2-32 recombinant adenoviruses
were replication-incompetent.
Novel mosaic BVDV antigens are recognized by multiple BVDV-specific
antibodies
Authenticity of the mosaic antigens (NproE21-3, NS2-31, and NS2-32) expressed by the recombi-
nant adenoviruses was confirmed by immunocytometric analysis of infected HEK-293A cells
probed with BVDV neutralizing monoclonal antibodies and polyclonal sera raised against
diverse BVDV strains (Fig 2). Anti-BVDV polyclonal sera from immunized goat and cattle
reacted with all three recombinant antigens (NproE21-3, NS2-31, and NS2-32), whereas monoclo-
nal antibodies 26A and 348, specific for the glycoprotein E2, reacted with NproE21-3 antigen
only (Fig 2A). The outcome confirmed that neutralization epitopes in the mosaic NproE21-3
antigen were correctly expressed, and that the NS2-31 and NS2-32 mosaic antigens were specifi-
cally recognized by anti-BVDV polyclonal sera. Thus, these antigens were expected to induce
authentic BVDV-specific immune responses in cattle. This expected outcome was consistent
with previous demonstration that multicomponent mosaic antigens generated using this strat-
egy elicit broadly protective pathogen-specific immune responses [68–70].
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Novel mosaic BVDV antigens are recognized by BVDV-specific T
lymphocytes
The NproE21-3, NS2-31, and NS2-32 antigens stimulated robust proliferation of PBMCs from
BVDV-immunized steers (Fig 3). The recall responses stimulated by the mosaic antigens were
significantly (P<0.01) higher than the responses elicited by whole killed BVDV-1b or BVDV-
2, suggesting that the mosaic antigens are likely to prime and amplify robust antigen-specific
immune responses in vivo (Fig 3). These outcomes showed that the mosaic antigens were
properly processed to generate peptides that were presented by MHC molecules to cognate
BVDV-specific memory T-cells. Previous studies have shown that mosaic antigens are pro-
cessed by host APCs to generate relevant peptides for MHC presentation to elicit protective T-
cell responses [71, 72].
Fig 1. BVDV antigen expression constructs. A) Schematic diagram of expression cassettes encoding
BVDV mosaic antigens: i) Composition of the nproe21-3, chimeric gene: npro encodes Npro antigen; e21
encodes a mosaic BVDV-1a E2 envelope glycoprotein; e22 encodes a mosaic BVDV-1b E2 envelope
glycoprotein; whereas e23 encodes a mosaic BVDV-2 E2 envelope glycoprotein. ii) ns2-31 encodes a mosaic
BVDV-1 nonstructural protein 2–3. iii) ns2-33 encodes a mosaic BVDV-2 nonstructural protein 2–3. A gene
(flag) encoding the FLAG tag was fused in-frame at the 3’ end of each chimeric gene for tracking protein
expression and transcription was under the direction of the CMV promoter (CMVp). The genes were cloned
into adenovirus backbone plasmid vector and the resultant constructs were designated pAdNproE21-3,
pAdNS2-31, and pAdNS2-32, respectively. B) Protein expression by recombinant plasmid constructs: The
plasmid DNA constructs encoding the three genes described in (A) above were transfected into HEK-293A
cell monolayers and protein expression was evaluated by immunocytometric analysis using anti-FLAG M2-AP
Conjugate as follows: HEK-293A cells monolayers were transfected with the following constructs: i)
pAdNproE21-3; ii) pAdNS2-31; iii) pAdNS2-32; and iv) pAd vector (negative control). C) Protein expression by
recombinant adenovirus constructs: HEK-293A cells monolayers were infected with the following recombinant
adenovirus: i) AdNproE21-3; ii) AdNS2-31; iii) AdNS2-32; and iv) Ad-Luciferase. Protein expression was
evaluated by immunocytometric analysis as above.
doi:10.1371/journal.pone.0170425.g001
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Mosaic antigens elicited stronger BVDV-specific T-cell immune
responses
Immunogenicity and protective efficacy of the AdNproE21-3, AdNS2-31, and AdNS2-32 recombi-
nant adenovirus cocktail, designated AdBVDV, was evaluated in steers using a homologous
prime-boost immunization regimen (Table 1 and Fig 4). One week after the AdBVDV vacci-
nees were boosted, the cocktail elicited higher, but not significantly different, BVDV-specific
IFN-γ-secreting PBMCs as well as BVDV-specific PBMC proliferation compared to the vacci-
nees that received the commercial MLV BVDV vaccine (Fig 5A & 5C). The mean responses
mounted by the AdBVDV vaccinees, but not the MLV vaccinees, were significantly higher
(P<0.05) than the negative controls. Before challenge (five months after the AdBVDV vacci-
nees were boosted) the AdBVDV-induced mean IFN-γ+ response had increased and was sig-
nificant (P<0.05) compared to the negative controls, whereas the mean IFN-γ+ response in
the MLV vaccinees had already declined (Fig 5B). This decrease in the mean IFN-γ response
in the MLV BVDV vaccine treatment group one week before challenge, might have had an
impact on clearance of the challenge virus.
Fig 2. Validation of B-cell epitopes in the mosaic BVDV antigens. Authenticity of the adenovirus-
expressed novel BVDV mosaic antigens was confirmed by immunocytometric analysis using E2-specific
neutralizing monoclonal antibodies 26A and 348 (both neutralize BVDV-1 & 2); bovine anti-BVDV hyper-
immune serum (generated by immunizing steers multiple times with BVDV-1 & 2 vaccines followed by
boosting with killed diverse BVDV-1 & 2 strains and then challenged with wild type BVDV-1 & 2 strains (The
sera have high BVDV-1 & 2 neutralizing titers [59]); and goat anti-BVDV polyclonal serum generated against
multiple wild-type BVDV-1 & 2 strains. A) HEK-293A cells expressing NproE21-3; B) HEK-293A cells
expressing NS2-31; C) HEK-293A cells expressing NS2-32; and D) HEK-293A cells expressing luciferase.
doi:10.1371/journal.pone.0170425.g002
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The mean BVDV-specific PBMC proliferation increased in both the vaccinated groups, but
only the AdBVDV- and not the MLV-induced response was significantly different (P<0.05)
from the AdLuc control group (Fig 5D). The increase in mean IFN-γ response and PBMC pro-
liferation in the AdBVDV treatment group at five months post-boost, were not significantly
different from the responses recorded at one week post-boost (Fig 5).
Mosaic antigens elicited cross-protective BVDV-specific antibody
responses
Following boosting of the AdBVDV vaccinees, the levels of BVDV neutralizing serum antibod-
ies against five BVDV-1 strains and three BVDV-2 strains were evaluated at one-week post-
boost and one-week pre-challenge (Figs 6 and 7). The adenovirus cocktail induced higher
mean neutralizing antibody titers post-boost against all BVDV-1 strains compared to the
Fig 3. Validation of mosaic antigens using BVDV-specific T-cells. Authenticity of T-cell epitopes in the
mosaic BVDV antigens was validated by proliferation assay using PBMCs from a BVDV-1 & 2 hyper-immune
steer [59]. The data shown is minus background counts from negative control (media alone) treatment. The
asterisks denote a statistically significant difference (P<0.01) between the proliferation induced by the
NproE21-3, NS2-31 and the NS2-32 antigens and both whole killed viruses BVDV-1b and BVDV-2. This outcome
is representative of assays conducted using PBMCs from other BVDV immune steers.
doi:10.1371/journal.pone.0170425.g003
Fig 4. Immunization timeline. On day -228 pre-challenge, cattle in the treatment group were vaccinated with a cocktail of the
recombinant adenoviruses expressing mosaic BVDV antigens (AdBVDV), whereas positive control cattle received a
commercial MLV BVDV vaccine. Negative control cattle were inoculated with the recombinant AdLuc. On day -149 pre-
challenge, the cattle were boosted with the respective priming inoculum and dose (Table 1). On day 0, all the cattle were
challenged by intranasal delivery of a BVDV-1373 using an atomizer. Blood samples were collected on selected days (0, 3, 6,
10, 12, 13 and 15), whereas clinical observations and rectal temperatures were monitored and recorded daily from days 1–15
post-challenge.
doi:10.1371/journal.pone.0170425.g004
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responses stimulated by the commercial MLV BVDV vaccine and the AdLuc controls. The dif-
ference between the mean titers however, was significant only for the non-cytopathic BVDV-
1b BJ (P<0.05) and BVDV CA0401186a strains (AdBVDV vs MLV, P<0.05; AdBVDV vs
AdLuc, P<0.01) (Fig 6A). Furthermore, the mean AdBVDV titers increased up to five months
post-boost (one-week pre-challenge) against 4 of 5 BVDV-1 strains whereas, the mean MLV
titers either remained the same or declined. These mean AdBVDV titers remained signifi-
cantly higher (P<0.05) than the MLV vaccinees and the AdLuc controls for the BJ strain, and
only the AdLuc controls for the cytopathic BVDV-1a NADL strain. Interestingly, for all three
BVDV-2 strains, the mean titers of the MLV vaccinees were higher (in contrast to BVDV-1)
than the AdBVDV vaccinees post-boost. These mean MLV titers were significantly higher
(P<0.05) than the AdBVDV vaccinees only for strain A125 and significantly higher than the
AdLuc controls for all three strains (P<0.05 for strain 890; P<0.01 for strains 1373 and A125).
The mean BVDV-2-specific titers in both the AdBVDV vaccinees as well as the MLV vaccinees
increased before challenge. Thus overall, the AdBVDV vaccine cocktail was able to induce
high titers against all 8 BVDV strains tested in 3 out of 5 calves, whereas the MLV vaccine was
able to induce high titers against only BVDV-2 strains. It is also noteworthy that the 3
AdBVDV vaccinees had substantially higher neutralizing titers (1:1024–1:2048) when com-
pared to the MLV vaccinees (1:32–1:256) against the NADL strain which is a component of
the commercial MLV vaccine they received.
Fig 5. Mosaic BVDV vaccine elicited strong T-cell responses. Immunization of cattle with adenovirus-
vectored mosaic BVDV vaccine primed and expanded BVDV-specific T-cells. A commercial MLV BVDV
vaccine served as a positive control, whereas AdLuciferase served as a negative control. EliSpot assays were
used to evaluate BVDV-specific IFN-γ-secreting PBMC responses against defined BVDV T-cell epitopes and
data is shown for A) One-week post-boost; and B) Day 0 of challenge. Outcome is presented as IFN-γ+ SFC/
106 PBMC. Cell proliferation assays were used to evaluate BVDV-specific PBMC responses and data is
shown for C) One-week post-boost; and D) one-week pre-challenge. Proliferation of the PBMCs in response
to defined BVDV T-cell epitopes is presented as the means ± standard deviations of 3H-thymidine
incorporation by the cells from triplicate wells. In both assays, medium alone served as the negative control
and the data shown is minus media background counts. The group mean is represented by a bar. Asterisks
denote statistically significant differences, *P<0.05.
doi:10.1371/journal.pone.0170425.g005
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Fig 6. Mosaic BVDV vaccine induced BVDV-1 specific neutralizing antibodies. Serum neutralization
assays were used to evaluate BVDV-1-specific neutralization titers at A) One-week post-boost; and B) one-
week pre-challenge against five BVDV type 1 strains. Mean group titers are represented by the bars.
Statistically significant differences between the groups are denoted by asterisks. *P<0.05; **P<0.01.
doi:10.1371/journal.pone.0170425.g006
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Clinical observations, hematology and viremia
Following the BVDV challenge, there were no obvious differences in clinical score among all
the animals, however, characteristic biphasic pyrexia was observed for the negative controls
but not for the AdBVDV or the MLV vaccinees (Fig 8A). On day 5 post-challenge, the tran-
sient rise in mean rectal temperatures of the negative controls was significantly higher
(P<0.001) than the MLV vaccinees but not the AdBVDV vaccinees. The mean rectal tempera-
tures for the negative controls rose again on day 9, peaked at day 10 and normalized by day 11
post-challenge. The mean temperatures of the controls were significantly higher than
AdBVDV vaccinees on days 9 (P<0.05) and 10 (P<0.001) post challenge, and the MLV vacci-
nees on days 8 (P<0.01), 9 (P<0.001) and 10 (P<0.001) post-challenge (Fig 8A). The negative
control animals also exhibited transient leucopenia from days 6 to 9 post-challenge with a 32–
40% reduction against baseline (day 0) white blood cell (WBC) counts. This reduction of
WBCs in the negative controls was significant compared to the AdBVDV vaccinees on days 6
(P<0.05) and 9 (P<0.01) post-challenge, and the MLV vaccinees on days 6 (P<0.01), 7
(P<0.01) and 9 (P<0.001) post-challenge (Fig 8B). There was no significant difference in
Fig 7. Mosaic BVDV vaccine induced BVDV-2 specific neutralizing antibodies. BVDV-2-specific
neutralization titers against three BVDV type 2 strains were evaluated at A) two weeks post-boost; and B) one
week pre-challenge. Mean group titers are represented by the bars. Statistically significant differences
between the groups are denoted by asterisks *P<0.05; **P<0.01.
doi:10.1371/journal.pone.0170425.g007
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platelet counts among the treatment groups post-challenge. On days 7 and 10 post-challenge,
no virus was detected in all the AdBVDV vaccinees (Table 2). However, BVD virus was
detected from the blood of one of the steers that received the commercial MLV BVDV vaccine
on day 7 but not on day 10 post-challenge, and from the blood of all the negative controls up
to day 15 post-challenge (Table 2).
Recombinant adenovirus inoculated intradermally is short lived
Persistence of recombinant replication-incompetent adenovirus at the intradermal inoculation
site, the draining lymph node, and the spleen was monitored by HEK-293A cell-dependent
virus rescue followed by immunocytometric analysis using adenovirus-specific polyclonal
antibody. One-day post-inoculation, adenovirus was readily recovered from the skin biopsies
collected from the inoculation sites, but not from the control sites (Fig 9B and 9C). Virus
recovery decreased drastically by day two post-inoculation and very few viral particles were
recovered at day three (Fig 9E and 9H). No virus was recoverable from all skin biopsies col-
lected on days 4–7 post-inoculation (Fig 9K). Skin biopsies collected on days 14 and 21, and
draining lymph node and spleen samples collected on day 21 were all negative (Fig 9N and
9O). The medium from the HEK-293A cells used to test the samples collected on days 4–7, 14,
and 21, was negative after a second round of screening. These outcomes are consistent with
previous findings in rodents [73]. Given that ABSL2 biocontainment is required for in vivo
Fig 8. Clinical manifestations post-challenge. A) Mean rectal temperature fluctuation; and B) Mean
change ratios of white blood cell counts in the vaccinated and negative control groups post-challenge.
Asterisks denote statistically significant differences as compared to the negative controls. *P<0.05; **P<0.01
and ***P<0.001.
doi:10.1371/journal.pone.0170425.g008
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studies using the replication-incompetent adenovirus, data from this pilot study suggest that it
is safe to downgrade biocontainment after seven days post-inoculation. However, the fate of
the vector genome in cattle and environmental risk assessment will need to be determined.
Conclusions
The purpose of this study was to develop an efficacious prototype BVDV vaccine which a)
overcomes the several disadvantages associated with the MLV vaccine mentioned previously
and b) provides broad protection against multiple BVDV genotypes. To this end, we designed
mosaic polypeptide consensus sequences of highly immunogenic BVDV antigens such as Npro,
E2 glycoprotein and the Nonstructural protein 2–3 based on multiple genotypes. We selected
live replication deficient adenovirus as a vector for delivery of these antigens to prime strong
humoral as well as cell mediated immune responses. Polyclonal anti-BVDV sera and monoclo-
nal anti-E2 antibodies strongly recognized these mosaic antigens by immunocytometric analy-
sis. Furthermore, PBMCs from BVDV immune steers proliferated strongly upon stimulation
by these mosaic antigens. The above outcomes confirmed the authenticity of both B-cell and
T-cell epitopes in all the mosaic antigens.
Calves immunized with a cocktail of recombinant adenoviruses expressing these antigens
had stronger IFN-γ+ and proliferation responses to defined BVDV CD4+ T-cell epitopes as
compared to calves vaccinated with the commercial BVDV MLV vaccine. In addition, the
AdBVDV vaccinees had higher serum neutralizing titers against BVDV-1 than the MLV vacci-
nees. In case of BVDV-2, the MLV vaccinees had higher mean titers one week post-boost, but
the AdBVDV mean titers increased over time and before challenge were equivalent or higher
than the MLV vaccinees for 2 of 3 strains tested. Importantly, both BVDV-1 and BVDV-2 neu-
tralizing antibody titers along with the cellular IFN-γ+ and proliferation immune responses
considerably increased for up to five months post-boost (one week before challenge) in most
AdBVDV vaccinees, whereas only the BVDV-2 specific titers and the mean proliferation
Table 2. Virus isolation from calves on day 7 and day 10 post-challenge.
Cattle ID Vaccine Viremia
Day 7 post-challenge Day 10 post-challenge
4 AdBVDV - -
12 AdBVDV - -
13 AdBVDV - -
22 AdBVDV - -
23 AdBVDV - -
3 BVDV MLV - -
14 BVDV MLV - -
19 BVDV MLV - -
24 BVDV MLV - -
27 BVDV MLV + (10−2) -
10 AdLuciferase + (10−3) + (10−3)
18 AdLuciferase + (10−3) + (10−3)
25 AdLuciferase + (10−3) + (10−3)
28 AdLuciferase + (10−3) + (10−3)
29 AdLuciferase + (10−3) + (10−3)
Viremia in blood samples taken on days 7 and 10 post-challenge was evaluated by immunocytometric analysis of MBDK cells probed with goat anti-BVDV
polyclonal serum. The dilution at which the samples were positive is specified. Sample dilutions further than 10−3 were not tested.
doi:10.1371/journal.pone.0170425.t002
Live-Vectored BVDV Multi-Antigen-Based Vaccine
PLOS ONE | DOI:10.1371/journal.pone.0170425 January 18, 2017 16 / 23
Fig 9. Persistence of replication-incompetent adenovirus in cattle. Viable recombinant adenovirus
inoculated intradermally is only recoverable within three days. Presence of adenovirus rescued from tissue
samples of four steers at defined time points was tracked by immunocytometric analysis of HEK-293A cells.
Representative data from one steer is shown: A, D, G, J, and M are positive controls at 24 hr., 48 hr., 72 hr.,
day 7, and day 21, respectively. B, E, H, and K, are skin biopsies taken from the inoculation sites on the neck
of the steers at 24 hr., 48 hr., 72 hr., and day 7, respectively, whereas C, F, I, and L, are cognate control skin
biopsies taken concurrently from the flank. N and O are draining lymph node and spleen samples,
respectively, collected three weeks post-inoculation.
doi:10.1371/journal.pone.0170425.g009
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responses amplified in the MLV vaccinees. Upon challenge with a BVDV-2a strain, both vacci-
nated groups showed no clinical signs of infection. The negative controls however, had a mild
fever on day 5 post-challenge followed by a more severe pyrexia on day 10 post-challenge.
Moreover, the negative controls also had significantly lower WBC counts than both vaccinated
groups. Rapid clearance of virus is an attractive trait in a BVDV vaccine. All the AdBVDV vac-
cinees had cleared the virus as early as 7 days post-challenge, whereas one MLV vaccinee was
still viremic on day 7 but not on day 10 post-challenge. All negative controls remained viremic
up to day 15 post-challenge. With regards to the safety concern and ABSL2 biocontainment
when using human Ad5 as a delivery vector, we showed that the replication-incompetent Ad5
virus is cleared from the inoculation site within four days post-injection and is not recovered
from either the draining lymph node or the spleen after 21 days post-inoculation.
Overall, data from this study showed that the AdBVDV prototype vaccine is more immuno-
genic and offers better cross-protection than the commercial MLV vaccine in terms of cell
mediated and neutralizing antibody responses. As far as protective efficacy is concerned, the
AdBVDV vaccine performed at par if not better than the MLV vaccine upon challenge by
BVDV-2a strain. Notably, this study is the first to report heterologous protection using subunit
BVDV vaccines. Future studies with larger animal sample sizes, different vaccine doses and
challenge with diverse BVDV strains need to be conducted to further optimize the AdBVDV
prototype vaccine.
The protective potential of the BVDV E2 antigen has been successfully demonstrated in the
past using various delivery platforms like live-vectors, DNA immunizations or as a recombi-
nant protein produced in different expression systems [74–77]. Current efforts are now
focused on enhancing this potential using modern adjuvants and antigen carriers such as PRR
activators, APC targeting molecules and silica nanoparticles [78–81]. This study highlights the
cross-protective potential of the novel mosaic polypeptides and is the first to report heterolo-
gous protection using subunit BVDV vaccines. Thus, future studies using these mosaic poly-
peptide sequences in conjunction with modern immune-response enhancing strategies may
lead to a very effective and cross-protective BVDV vaccine.
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